Esophageal adenocarcinoma section visualised by multiplexed immunofluorescence, showing cell nuclei (greyscale) and micronuclei (aberrant nuclear structures formed when chromosomes are improperly segregated during cell division; red) interspersed throughout the malignant cell compartment (cyan). Infiltrating macrophages are shown in yellow.
Image Credit: Parkes Lab, Translational Histopathology Laboratory, University of Oxford.
Scientific Frontline: Extended "At a Glance" Summary: Chromosomal Instability in Esophageal Adenocarcinoma
The Core Concept: Highly aggressive esophageal cancers are fundamentally characterized by elevated chromosomal instability, a state where cancer cells continuously make genetic errors during division, thereby accelerating their growth and adaptability.
Key Distinction/Mechanism: Rather than merely driving rapid cellular proliferation, chromosomal instability alters the tumor's interaction with the host immune system. Unstable cancer cells activate specific genes to release chemical signals that attract inflammatory immune cells, effectively hijacking the body's natural defense mechanisms to fortify the tumor and resist medical treatments.
Major Frameworks/Components:
- Chromosomal Instability: The frequent missegregation of chromosomes during cell division, which results in aberrant nuclear structures such as micronuclei scattered throughout the malignant cell compartment.
- cGAS-Chemokine-Myeloid Axis: The specific signaling pathway utilized by chromosomally unstable cells to emit chemical signals and attract supportive inflammatory immune cells (like macrophages) into the tumor.
- Tumor Microenvironment: The local biological environment heavily reshaped by the tumor to support its survival, driven by hijacked immune responses rather than effective immune attacks.
Branch of Science: Oncology, Genetics, Immunology, and Medical Sciences.
Future Application: The identification of this hijacked inflammation pathway provides a distinct therapeutic vulnerability. Future targeted therapies and immunotherapies can be engineered to disrupt the cGAS-chemokine-myeloid axis, stripping the tumor of its hijacked immune defenses and rendering it susceptible to conventional treatments.
Why It Matters: This discovery critically explains why certain aggressive forms of esophageal cancer exhibit profound resistance to existing therapies. By mapping the exact mechanism by which these tumors exploit immune inflammation, researchers have opened the door to novel treatment options that could significantly improve patient outcomes and survival rates.
Research published in Science Advances has uncovered new insights into why the most aggressive esophageal cancers are so difficult to treat and how the body’s own defense systems are helping them to thrive.
The study, led by Professor Eileen Parkes and her team in the Department of Oncology at the University of Oxford, analyzed patient-donated tumor samples and found that the most dangerous types of esophageal cancers share a key feature: high chromosomal instability. This means the cancer cells constantly make mistakes as they grow and divide, making them more aggressive, harder to treat, and allowing them to adapt more easily.
However, the research team discovered that this instability doesn’t just make the cancer grow faster: it also changes how the tumor interacts with the body’s own defense systems.
Using newly developed laboratory models of esophageal cancer, the researchers found that cancers with unstable chromosomes ‘switch on’ certain genes. These genes were shown to send out chemical signals that attracted inflammatory immune cells into the tumor, bolstering its defense.
“We’ve known for some time that chromosomal instability makes cancer more aggressive, but what we’ve discovered is that it also fuels inflammation in esophageal cancer in a way that actually helps the tumor,” said Dr Bruno Beernaert, postdoctoral researcher in the Parkes lab and DPhil in Cancer Science alumnus. 'Instead of triggering an effective immune attack against itself, the cancer appears to hijack the body’s own defense systems, the immune response, to help it to survive treatment and spread.'
The findings may help to explain why some of the most aggressive types of esophageal cancers are particularly resistant to existing therapies and point to new potential treatment strategies.
“By uncovering how chromosomal instability reshapes the tumor's immune environment, we’ve identified a potential vulnerability,” added Professor Parkes. “If we can disrupt this inflammation pathway, we may be able to suggest new treatment options which improve outcomes for patients.”
Published in journal: Science Advances
Title: New research reveals why some esophageal cancers are so hard to treat
Authors: Bruno Beernaert, Rose L. Jady-Clark, Parin Shah, Erik Ramon-Gil, Nora M. Lawson, Zack D. Brodtman, Somnath Tagore, Frederik Stihler, Alfie S. Carter, Shannique Clarke, Tong Liu, Winston M. Zhu, Juliet E. Martin, Erkin Erdal, Alistair Easton, Leticia Campo, Molly Browne, Stephen Ash, Rabial Q. Raja, Nicola Waddell, Tom Crosby, Simon R. Lord, Derek A. Mann, Ignacio Melero, Carlos E. De Andrea, Andréa E. Tijhuis, Floris Foijer, Ester M. Hammond, Kadir C. Akdemir, Jack Leslie, Benjamin Izar, and Eileen E. Parkes
Source/Credit: University of Oxford
Reference Number: ongy031426_01